The Challenge
After receiving standard-of-care chemoimmunotherapy and undergoing a bone marrow transplant that failed almost immediately, Robin faced very limited treatment options and an urgent need for a new approach.
Our Impact
Cancer Commons reviewed the case, provided reassurance and clarity, and strongly encouraged participation in a CAR-T trial based on highly promising preliminary results.
The Outcome
The patient enrolled in a CAR-T trial and achieved a complete response. Robin remains cancer-free more than five years later and the CAR-T therapy from the clinical trial was FDA-approved 1.5 years after this patient's remission, making them an early success story.
